First Watch Restaurant Group, Inc. announced the appointment of Ashlee Weisser as its new Chief Financial Officer. This announcement was made via Refinitiv and is a brief report on the personnel change within the company.

This article provides the net asset value (NAV) table for the FT Vest U.S. Equity Moderate Buffer ETF - December (GDEC). It lists both market price and NAV, along with daily figures for the past 30 days, and includes general disclaimers about investment performance and data accuracy.

Ameriprise Financial (AMP) is a large-cap diversified financial services company specializing in advice-driven financial planning. Despite a strong Q1 2026 earnings report, AMP stock has significantly underperformed the Dow Jones Industrial Average (DOWI) and its rival Raymond James Financial (RJF) over the last three months, 52 weeks, and year-to-date. Analysts, however, remain moderately optimistic with a consensus "Moderate Buy" rating and a price target suggesting a 20.2% upside.

Moderna and the University of Oxford have received UK authorization to begin a Phase 1/2 study of mRNA-4194, an investigational mRNA cancer vaccine for individuals with Lynch syndrome. This inherited condition significantly increases cancer risk, and the vaccine aims to prevent cancer development by generating immune responses against early cancer growth. The trial, funded by Moderna and sponsored by the University of Oxford, is part of a broader strategic partnership with the UK Government to advance mRNA research and enhance pandemic preparedness.

Morgan Stanley analyst Christopher Snyder has increased the price target for Dover Corporation (DOV) shares to $230 from $210, reiterating an Equal Weight rating. This adjustment follows Dover's strong Q1 2026 performance, which included double-digit revenue growth, $2.5 billion in bookings (up 24% year-over-year), and a book-to-bill ratio of 1.2 across all business segments. The company reported adjusted earnings of $2.28 per share, up 11% year-over-year, and maintains its goal for double-digit adjusted EPS growth for the full year.

Levi & Korsinsky, LLP is alerting Globant S.A. stockholders about a securities class action lawsuit alleging inadequate risk disclosures between February 15, 2024, and August 14, 2025. The lawsuit claims that while Globant touted talent retention, it had allegedly frozen wages, experienced client defections, and failed to integrate an acquisition, leading to a significant stock price decline. Investors who suffered losses have until June 23, 2026, to act as lead plaintiff.

This article provides an overview of top gainers and losers in the after-hours trading session following the US market close on Monday. It lists companies like CL WORKSHOP GROUP LTD (NWGL) and VCI GLOBAL LTD (VCIG) as significant gainers, and ITONIC HOLDINGS LTD (ITOC) and PARK HA BIOLOGICAL TECH-A (BYAH) among the biggest losers, detailing their percentage changes and offering brief commentary on each.

Jefferson Shreve, representing Indiana's 6th congressional district, recently made significant investments in structured notes from JP Morgan and Morgan Stanley. These investments, valued between $5 million and $25 million for JP Morgan and between $1 million and $5 million for Morgan Stanley, highlight his confidence in these financial institutions and an interest in structured notes as investment vehicles. The transactions were disclosed in a congressional trade report certified on June 6, 2026, adhering to the STOCK Act.

Silver Lake-affiliated holders have filed a Form 144 indicating both past sales and a planned sale of Dell Technologies Inc. (DELL) Class C Common Stock. The filing details a future sale of 138,888 shares on June 8, 2026, which were acquired through the conversion of Class B Common Stock originally obtained in 2016. Additionally, the document records numerous open-market dispositions by various Silver Lake entities between March and June 2026, including significant tranches like 274,335 shares sold by Silver Lake Partners IV, L.P. on June 1, 2026.

Bank of Montreal (TSX:BMO) recently reported strong Q2 results, leading to a higher quarterly dividend and significant share price returns. While the stock trades near analyst price targets, with a mainstream narrative suggesting it's 2% overvalued at CA$229.65 based on a CA$225.11 fair value, Simply Wall St's discounted cash flow analysis indicates a fair value of CA$247.50, implying a 7.2% discount. Investors are advised to consider various valuation models and potential risks like slower Canadian growth or credit pressures.